Search Results

You are looking at 111 - 120 of 491 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

within 5 years of diagnosis. Carcinoids are generally slow-growing tumors, but in the advanced setting can be very disabling and impact quality of life (QoL) due to diarrhea, bowel obstructions, pain, weight loss, depression, and fatigue. Many of the

Full access

REMS. The table below reflects a sample of drugs recently added that may be used for a supportive care indication (e.g., pain, cancer-related fatigue) in a patient with cancer. All the drugs listed require the provision of a medication guide detailing

Full access

, but in the advanced setting can be very disabling and can impact quality of life (QOL) due to diarrhea, bowel obstructions, pain, weight loss, depression, and fatigue. Many of the abdominal symptoms are caused by the dense adhesions. Midgut carcinoids

Full access

Barry D. Bultz, Amy Waller, Jodi Cullum, Paula Jones, Johan Halland, Shannon L. Groff, Catriona Leckie, Lisa Shirt, Scott Blanchard, Harold Lau, Jacob Easaw, Konrad Fassbender, and Linda E. Carlson

integrated into regular clinical practice and run by frontline clinic staff. Screening was linked with follow-up care and services, including psychosocial resources, pain and fatigue clinics, nutrition services, and palliative care, using referral guidelines

Full access

David Cella, Sarah K. Rosenbloom, Jennifer L. Beaumont, Susan E. Yount, Diane Paul, Debra Hampton, Amy P. Abernethy, Paul B. Jacobsen, Karen Syrjala, and Jamie H. Von Roenn

symptoms specific to a given tumor can represent efficacy in achieving a meaningful patient outcome. Most validated measures of cancer-specific quality of life incorporate an assessment of certain prevalent symptoms, such as pain and fatigue, within a

Full access

Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O’Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, and Hema Sundar

confounded by fatigue, depression, anxiety, underlying brain tumors, endocrine dysfunction, nutritional deficiency, alcohol use, and sleep disturbances. 50 Therefore, if dementia is suspected, further evaluation including brain imaging, neuropsychological

Full access

David S. Ettinger

%, respectively. The most common side effects of nivolumab were fatigue, musculoskeletal pain, decreased appetite, cough, and constipation. Eighty-three patients had tumor samples suitable for PD-L1 expression analysis. Across the prespecified expression levels

Full access

Linda Overholser and Carlin Callaway

unmet needs after treatment. Many patients have also suffered physical side effects and have seen the relationships in their lives undergo dramatic shifts. Patients’ needs often relate to quality of life (fatigue, fear of recurrence) and/or their ability

Full access

Andrew J. Armstrong

men that were evaluated,” explained Dr. Armstrong. Fatigue, fall risk, and hypertension were the most common clinically relevant adverse events associated with enzalutamide treatment. 7 In fact, hypertension occurred 2 to 3 times as often with

Full access

Thomas Olencki

SCC. A phase II study was conducted at his center, but was discontinued due to overwhelming fatigue, anorexia, weight loss, and pleural effusion. Other therapies appear to offer more promise in the treatment of cutaneous SCC. Dr. Olencki discussed